Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Phillips Discusses Past Progress and Previews the Future in Hematologic Cancers

July 10th 2024

Tycel Phillips, MD, highlights key takeaways in NHL, MDS, and myelofibrosis from an OncLive State of the Science Summit on hematology.

Dr Phillips on the Evolution of BTK Inhibitors in MCL

July 3rd 2024

Tycel Phillips, MD, discusses the evolution of treatment with BTK inhibitors for patients with mantle cell lymphoma.

Dr Kamdar on the TRANSCEND NHL 001 Trial of Liso-Cel in Relapsed/Refractory MCL

July 1st 2024

Manali Kamdar, MD, discusses the patient population included in the mantle cell lymphoma cohort of the phase 3 TRANSCEND NHL 001 trial.

Dr Phillips on the Evolution of the MCL Treatment Paradigm

June 28th 2024

Tycel Phillips, MD, discusses the evolution of treatment for patients with mantle cell lymphoma.

Liso-Cel Elicits Clinically Meaningful Activity in Heavily Pretreated, Relapsed/Refractory MCL

June 20th 2024

Liso-cel demonstrated clinically meaningful activity regardless of the number of previous lines of systemic therapy or response to prior BTK inhibitors in MCL.

Zanubrutinib/Rituximab Induction Before Short-Course R-DHAOx Draws Responses in Mantle Cell Lymphoma

June 19th 2024

Frontline zanubrutinib/rituximab induction followed by short-course chemotherapy yielded efficacy in mantle cell lymphoma.

Fixed-Duration Glofitamab Yields Responses in R/R Mantle Cell Lymphoma

June 18th 2024

Tycel Phillips, MD, discusses updated findings from a phase 1/2 trial evaluating glofitamab in relapsed/refractory mantle cell lymphoma.

Frontline Acalabrutinib/BR Regimen Significantly Improves PFS in Mantle Cell Lymphoma

June 17th 2024

Frontline treatment with acalabrutinib and bendamustine/rituximab (BR) improved PFS over BR alone in older patients with mantle cell lymphoma.

Zanubrutinib Plus Obinutuzumab/Venetoclax Is Safe, Elicits Responses in Older Patients With Untreated MCL

June 15th 2024

The combination of zanubrutinib, obinutuzumab, and venetoclax was safe and well-tolerated in older patients with untreated mantle cell lymphoma.

Liso-Cel Associated With Improved Benefit in Earlier Lines of Therapy in R/R Mantle Cell Lymphoma

June 14th 2024

Clinically meaningful activity was found across all subgroups in a posthoc subgroup analysis of patients with MCL treated with liso-cel.

Dr Phillips on the Safety and Efficacy of Glofitamab in Relapsed/Refractory MCL

June 6th 2024

Tycel Phillips, MD, MPH, discusses updated efficacy and safety data with glofitamab for the treatment of relapsed/refractory mantle cell lymphoma.

OncLive’s May Roundup of Key FDA Approvals in Oncology

May 31st 2024

Here is your guide to important regulatory approvals made by the FDA in May 2024.

Dr Gordon on the FDA Approval of Liso-Cel in Relapsed/Refractory MCL

May 30th 2024

Leo I. Gordon, MD, discusses the significance of the FDA approval of liso-cel for patients with relapsed/refractory mantle cell lymphoma.

FDA Approves Liso-Cel for R/R Mantle Cell Lymphoma After 2 Lines of Therapy

May 30th 2024

The FDA approved liso-cel for the treatment of adult patients with relapsed/refractory mantle cell lymphoma after at least 2 prior lines of therapy, including a BTK inhibitor.

Adding Ibrutinib to Chemoimmunotherapy Induction Improves FFS in Younger MCL

May 20th 2024

The addition of ibrutinib to chemoimmunotherapy induction with ASCT improved rates of failure-free survival in younger patients with mantle cell lymphoma.

Dr Koff on Toxicities Associated With Pirtobrutinib in MCL

May 15th 2024

Jean L. Koff, MD, MS, discusses the toxicities associated with pirtobrutinib in the BRUIN trial for mantle cell lymphoma.

Retrospective Analysis Shows Efficacy and Safety of CAR T-Cell Therapy in MCL With SCNS

May 14th 2024

CAR T-cell therapy is effective and tolerable in patients with mantle cell lymphoma with secondary central nervous system involvement.

Efficacy and Safety of Pirtobrutinib Continue to Reshape MCL Treatment Paradigm

May 13th 2024

Jean L. Koff, MD, MS, discusses key considerations in the choice of BTK inhibitors for frontline and maintenance treatment in MCL.

Frontline Acalabrutinib Plus Chemoimmunotherapy Elicits Meaningful Survival Benefit in MCL

May 2nd 2024

Acalabrutinib plus bendamustine and rituximab (BR) led to a statistically significant improvement in PFS vs BR for treatment-naive mantle cell lymphoma.

Dr Pearse on the Current Treatment Paradigm for Relapsed/Refractory MCL

April 18th 2024

William B. Pearse, MD, discusses the current treatment paradigm for patients with relapsed/refractory mantle cell lymphoma.